Animal models testing monotherapy versus combination antifungal therapy: Lessons learned and future directions

Current Opinion in Infectious Diseases

Volumn 19, Issue 4, 2006, Pages 360-364

  Clemons, Karl V ^a,b,c   Stevens, David A ^a,b,c  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b CALIFORNIA INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal models; Antifungal combination therapy; Experimental antifungal therapy

Indexed keywords

ALLYLAMINE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; COLONY STIMULATING FACTOR 1; CYCLOPHOSPHAMIDE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 12; ITRACONAZOLE; MICAFUNGIN; NIKKOMYCIN Z; POLYENE; RAVUCONAZOLE; RIFAMPICIN; STEROID; TRIAMCINOLONE; VORICONAZOLE;

ANIMAL MODEL; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; DRUG EFFICACY; IMMUNOMODULATION; LUNG ASPERGILLOSIS; LUNG MYCOSIS; MONOTHERAPY; MYCOSIS; NONHUMAN; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALS; ANTIFUNGAL AGENTS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; IMMUNOTHERAPY; MICE; MYCOSES;

EID: 33745588839     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000235163.70678.59     Document Type: Review

References (59)

1. Walsh TJ, Groll A, Hiemenz J, et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10 (Suppl 1):48-66.
2. Walsh TJ, Groll AH. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis 1999; 1:247-261.
3. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004; 64:1997-2020.
4. Wingard JR, Leather H. A new era of antifungal therapy. Biol Blood Marrow Transplant 2004; 10:73-90.
5. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990; 12:1147-1201.
6. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003; 37 (Suppl 3):S188-S224.
7. Clemons KV, Stevens DA. The contribution of animal models of aspergillosis to understanding pathogenesis, therapy and virulence. Med Mycol 2005; 43 (Suppl 1):S101-S110.
8. Polak A. Experimental models in antifungal chemotherapy. Mycoses 1998; 41:1-30.
9. Sorensen KN, Clemons KV, Stevens DA. Murine models of blastomycosis, coccidioidomycosis, and histoplasmosis. Mycopathologia 1999; 146:53-65.
10. Stevens DA. Animal models in the evaluation of antifungal drugs. J Mycol Med 1996; 6 (Suppl I):7-10.
11. Stevens DA. Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis 1998; 26:1266-1269.
12. Clemons KV, Stevens DA. Overview of host defense mechanisms in systemic mycoses and the basis for immunotherapy. Semin Respir Infect 2001; 16:60-66.
13. De Pauw BE. New antifungal agents and preparations. Int J Antimicrob Agents 2000; 16:147-150.
14. Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003; 37 (Suppl 3):S157-S187.
15. Walsh TJ. Echinocandins - an advance in the primary treatment of invasive candidiasis. N Engl J Med 2002; 347:2070-2072.
16. Walsh TJ, Hiemenz JW, Anaissie E. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect Dis Clin North Am 1996; 10:365-400.
17. Walsh TJ, Viviani MA, Arathoon E, et al. New targets and delivery systems for antifungal therapy. Med Mycol 2000; 38 (Suppl 1):335-347.
18. Lachin JM. Worst-rank score analysis with informatively missing observations in clinical trials. Controlled Clin Trials 1999; 20:408-422.
19. Shih W. Problems in dealing with missing data and informative censoring in clinical trials. Curr Control Trials Cardiovasc Med 2002; 3:4.
20. Steinbach WJ, Perfect JR, Schell WA, et al. In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob Agents Chemother 2004; 48:3217-3225.
21. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39:797-802.
22. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225-234.
23. Capilla Luque J, Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother 2003; 47:1452-1455.
24. Clemons KV, Espiritu M, Parmar R, Stevens DA. Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005; 49:4867-4875.
25. Imai J, Singh G, Fernandez B, et al. Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model. J Antimicrob Chemother 2005; 56:166-171.
26. Graybill JR, Bocanegra R, Gonzalez GM, Najvar LK. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J Antimicrob Chemother 2003; 52:656-662.
27. Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187:1834-1843.
28. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46:2564-2568.
29. Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. Med Mycol 2006; 44:69-73.
30. Clemons KV, Martinez M, Stevens DA. Efficacy of itraconazole alone and in combination with amphotericin B against pulmonary aspergillosis. In: 4th Congress of the European Confederation of Medical Mycology. Glasgow, Scotland 1998. abstract 153.
31. Hanson LH, Perlman AM, Clemons KV, Stevens DA. Synergy between cilofungin and amphotericin B in a murine model of candidiasis. Antimicrob Agents Chemother 1991; 35:1334-1337.
32. Graybill JR, Bocanegra R, Najvar LK, et al. Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis. Antimicrob Agents Chemother 2003; 47:2373-2375.
33. Barchiesi F, Spreghini E, Baldassarri I, et al. Sequential therapy with caspofungin and fluconazole for Candida albicans infection. Antimicrob Agents Chemother 2004; 48:4056-4058.
34. Hossain MA, Reyes GH, Long LA, et al. Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. J Antimicrob Chemother 2003; 51:1427-1429.
35. Olson JA, Adler-Moore JP, Smith PJ, Proffitt RT. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob Agents Chemother 2005; 49:4895-4902.
36. Sugar AM, Hitchcock CA, Troke PF, Picard M. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob Agents Chemother 1995; 39:598-601.
37. Sugar AM, Salibian M, Goldani LZ. Saperconazole therapy of murine disseminated candidiasis: efficacy and interactions with amphotericin B. Antimicrob Agents Chemother 1994; 38:371-373.
38. Louie A, Banerjee P, Drusano GL, et al. Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole- susceptible or -resistant strains of Candida albicans. Antimicrob Agents Chemother 1999; 43:2841-2847.
39. Clemons KV, Stevens DA. Immunomodulation of fungal infections: do immunomodulators have a role in treating mycoses? EOS Rivista di Immunologia ed Immunofarmacologia 2002; 22:29-32.
40. Kullberg BJ. Trends in immunotherapy of fungal infections. Eur J Clin Microbiol Infect Dis 1997; 16:51-55.
41. Kullberg BJ, Anaissie EJ. Cytokines as therapy for opportunistic fungal infections. Res Immunol 1998; 149:478-488.
42. Joly V, Saint-Julien L, Carbon C, Yeni P. In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis. J Infect Dis 1994; 170:1331-1334.
43. Clemons KV, Lutz JE, Stevens DA. Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice. Antimicrob Agents Chemother 2001; 45:686-689.
44. Clemons KV, Lutz JE, Stevens DA. Efficacy of interferon-gamma and amphotericin B for the treatment of systemic murine histoplasmosis. Microbes Infect 2001; 3:3-10.
45. Lutz JE, Clemons KV, Stevens DA. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J Antimicrob Chemother 2000; 46:437-442.
46. Arruda C, Franco MF, Kashino SS, et al. Interleukin-12 protects mice against disseminated infection caused by Paracoccidioides brasiliensis but enhances pulmonary inflammation. Clin Immunol 2002; 103:185-195.
47. Clemons KV, Brummer E, Stevens DA. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother 1994; 38:460-464.
48. Kawakami K, Koguchi Y, Qureshi MH, et al. IL-18 contributes to host resistance against infection with Cryptococcus neoformans in mice with defective IL-12 synthesis through induction of IFN-gamma production by NK cells. J Immunol 2000; 165:941-947.
49. Kawakami K, Tohyama M, Xie Q, Saito A. IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin Exp Immunol 1996; 104:208-214.
50. Mencacci A, Cenci E, Bacci A, et al. Host immune reactivity determines the efficacy of combination immunotherapy and antifungal chemotherapy in candidiasis. J Infect Dis 2000; 181:686-694.
51. Rex JH, Bennett JE, Gallin JI, et al. In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J Infect Dis 1991; 163:849-852.
52. Zhou P, Sieve MC, Bennett J, et al. IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-gamma. J Immunol 1995; 155:785-795.
53. Deresinski SC. Granulocyte-macrophage colony-stimulating factor: potential therapeutic, immunological and antiretroviral effects in HIV infection. AIDS 1999; 13:633-643.
54. Clemons KV, Stevens DA. Treatment of orogastrointestinal candidosis in SCID mice with fluconazole alone or in combination with recombinant granulocyte colony-stimulating factor or interferon-gamma. Med Mycol 2000; 38:213-219.
55. Graybill JR, Bocanegra R, Luther M. Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis. Eur J Clin Microbiol Infect Dis 1995; 14:700-703.
56. Graybill JR, Bocanegra R, Najvar LK, et al. Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Antimicrob Agents Chemother 1998; 42:2467-2473.
57. Kullberg B-J, van't Wout JW, Hoogstraten C, van Furth R. Recombinant interferon-γ enhances resistance to acute disseminated Candida albicans infections in mice. J Infect Dis 1993; 168:436-443.
58. Nemunaitis J. Use of macrophage colony-stimulating factor in the treatment of fungal infections. Clin Infect Dis 1998; 26:1279-1281.
59. Pappas PG, Bustamante B, Ticona E, et al. Recombinant interferon-gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004; 189:2185-2191.